Determining the tumor KRAS status in a patient with stage IV CRC is important, because KRAS-mutant CRC is resistant to EGFR monoclonal antibodies (mAbs) as the mutant RAS continues the activation of the MAPK pathway downstream of EGFR-RAS. This evidence concerns the gene EGFR and neoplasm.